Skip to main content

Unfortunately we don't fully support your browser. If you have the option to, please upgrade to a newer version or use Mozilla Firefox, Microsoft Edge, Google Chrome, or Safari 14 or newer. If you are unable to, and need support, please send us your feedback.

We'd appreciate your feedback.Tell us what you think!(opens in new tab/window)

Elsevier
Publish with us

Blood Cancer UK

Elsevier and Blood Cancer UK have entered into an agreement which ensures authors publishing in Elsevier journals are compliant with this open access policy. Details about how to comply are outlined below.

Agreement

Blood Cancer UK requires electronic copies of any research articles that have been accepted for publication in a peer-reviewed journal to be made open access as soon as possible, and be available through Europe PubMed Central (Europe PMC) no later than six months after publication. This requirement applies to research supported in whole, or in part, by Blood Cancer UK which is published from 1 October 2014. The full open access policy of Blood Cancer UK is available here. (opens in new tab/window) UK authors may also be covered under the HEFCE open access policy and may wish to check additional open access policy here.

Authors can comply with Blood Cancer UK policy by publishing gold open access in either an Elsevier open access journal or in a subscription journal which supports open access publishing.

Gold open access

A publication fee is required to be paid in order to make an article gold open access. Blood Cancer UK, as part of the Charity Open Access Fund (COAF), indicate that authors should contact their host institution to access funds for open access. Researchers who receive funding from Blood Cancer UK, but who are not based at an institution that receives support from the COAF, may use any unspent grant money to pay for APCs or contact Blood Cancer UK to discuss further.

Elsevier's open access publication fees range between c$150 and c$9,900 US Dollars excluding tax and are journal specific — please refer to the guide for authors on the journal homepage. When publishing under either one of these open access options, the corresponding author will be given a choice of two Creative Commons licenses. Blood Cancer UK policy states that authors are required to select a Creative Commons Attribution (CC BY) license.

Upon publication, Elsevier will deposit the final published journal article in Europe PMC on behalf of the author. The version that appears in PMC will have a CrossMark® identifier and link back to the authoritative version of record on ScienceDirect.

Note: When publishing with Elsevier, the only way a researcher can comply with the Blood Cancer UK OA policy is to select the open access ("author pays") option. The Lancet, in addition to providing a hybrid OA option, also allows authors to self-archive that manuscript in PMC/Europe PMC after six months following publication.

Green open access

Note: When publishing with Elsevier, the only way a researcher can comply with the Blood Cancer UK OA policy is to select the gold open access option. The Lancet, in addition to providing a hybrid OA option, also allows authors to self-archive that manuscript in PMC/Europe PMC after six months following publication.

If you are a Blood Cancer UK funded author, and if any of your previously published Elsevier published articles prior to 1 October 2014 are not available in Europe PMC, then you may use Elsevier's sharing policy to deposit papers in this repository. Deposits made via this route must adhere to the journal-specific embargo. Such articles can be posted under a CC BY-NC-ND license.

Help and support